Adage Capital Partners Gp, L.L.C. Aligos Therapeutics, Inc. Transaction History

Adage Capital Partners Gp, L.L.C.

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$0.35 - $1.07 $887,423 - $2.71 Million	2,535,495 Added 102.88%	5,000,000 $1.75 Million
Q1 2024 May 15, 2024	BUY	$0.64 - $1.13 $1.58 Million - $2.78 Million	2,464,505 New	2,464,505 $2.42 Million
Q1 2023 May 15, 2023	SELL	$0.87 - $2.11 $217,500 - $527,500	-250,000 Reduced 16.97%	1,223,278 $1.06 Million
Q1 2022 May 16, 2022	BUY	$2.08 - $12.2 $3.06 Million - $18 Million	1,473,278 New	1,473,278 $3.17 Million

253K

Ticker ALGS
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 39,717,000
Market Cap $751M
Description
Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-010133, a s-antigen transport-inhibiting oligonucleotide polymer that is in Phase Ib clinical trial for the treatment of chronic hepatitis B (CHB);...

Get notified when there are updates to the investment portfolio of Adage Capital Partners Gp, L.L.C., based on Form 13F filings with the SEC.

Stay updated on Adage Capital Partners Gp, L.L.C. with notifications on news.